Key Highlights

  • BluGlass received an A$1.4 million Phase II contract from US photonics company Uviquity under a joint development agreement.
  • A new A$8.0 million R&D financing facility with Rockford replaced the A$2.27 million Radium facility, adding about A$5.4 million of liquidity.
  • Quarter-end cash was A$8.66 million, with customer receipts of $1.66 million and net operating cash outflow of $3.12 million.
  • The A$6.1 million FY26 R&D Tax Incentive refund arrived in October, with A$2.75 million applied to the Rockford loan.

BluGlass Limited (ASX:BLG), a vertically integrated developer and manufacturer of visible gallium nitride (GaN) lasers, released its activities update and Appendix 4C for the three months ended 30 September 2026 on 23 October 2026. The quarter featured a A$1.4 million Phase II contract, a refinanced R&D facility and a new early-stage collaboration with a global photonics leader.

Customer-Funded Programs Take Shape

Under its project-to-product model, BluGlass uses paid development engagements to address customer technical requirements and establish pathways to future product supply. In July it received a A$1.4 million (US$1.0 million) Phase II contract from US photonics company Uviquity under the companies' joint development agreement. Phase II extends the work beyond the first stage of research on Uviquity's integrated photonics platform to additional engineering, packaging, laser integration and purchases of BluGlass visible GaN lasers.

On 21 September the company announced an approximately A$286,000 (US$200,000) collaboration to co-develop a novel GaN-based device for scientific and medical markets. The feasibility study is expected to run three to five months and will assess how the companies' proprietary processes fit together.

Financing and Cash Position

In September BluGlass agreed terms for an A$8.0 million facility with Rockford RDF Pty Ltd, replacing the A$2.27 million Radium facility. The facility, fully drawn on 25 September, bears interest of 16.5% per annum and carries a 2.5% establishment fee, split between A$100,000 capitalised into the loan and A$100,000 payable in shares. It is secured over the FY26 and FY27 R&D Tax Incentive refunds, with limited featherweight security over other assets.

After quarter-end the company received its A$6.1 million FY26 refund, and A$2.75 million went to the scheduled loan repayment. The balance is repayable from the FY27 refund and no later than 1 March 2028.

Customer receipts were $1.66 million and net cash used in operating activities was $3.12 million. Cash and cash equivalents ended the quarter at A$8.66 million, against A$11.34 million at the start, and the Appendix 4C estimates 2.8 quarters of funding available.

Why This Could Matter

The company said the larger facility provides funding flexibility for working capital, customer-funded development and growth initiatives while it progresses commercialisation. Management said the engagements position it to move customer-funded development toward future product supply and to strengthen its presence in US markets.

Board Changes and Final Position

Jim Haden became Managing Director on 13 July, and Yam Rubenstein joined the Board as a Non-Executive Director on 21 August. Management presented to US investors at the iAccess Alpha conference on 15-16 September. The quarter leaves BluGlass with new development contracts, a refinanced facility and an updated cash balance.